Study guide

8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation

Key Takeaways Explain This Topic AI

Pregnancy signs are categorized into presumptive (subjective maternal symptoms: amenorrhea, fatigue, breast tenderness), probable (objective physical findings: Chadwick sign, Goodell sign, Hegar sign, positive hCG), and positive (definitive diagnostic proof: Doppler fetal heart tones, sonographic fetal visualization, examiner-palpated fetal movements).

The discriminatory zone is the maternal serum beta-hCG concentration (classically 1,500 to 2,000 mIU/mL; ACOG cautions it may be as high as 3,500 mIU/mL) at which a normal intrauterine gestational sac must reliably be visualized on transvaginal ultrasound (TVUS); absence of an intrauterine sac above this threshold warrants urgent evaluation for ectopic pregnancy or non-viable gestation.

First-trimester crown-rump length (CRL) measured via ultrasound is the single most accurate biometric parameter for establishing gestational age and estimated date of delivery (EDD), carrying an accuracy of ±5 to 7 days.

According to ACOG/SMFM guidelines, pregnancy dating is changed from the LMP-derived EDD if the ultrasound CRL differs by >5 days up to 8 6/7 weeks of gestation, or by >7 days from 9 0/7 to 13 6/7 weeks of gestation.

The initial prenatal laboratory evaluation mandates universal screening for blood type and Rh(D) status, indirect Coombs antibody screen, complete blood count, rubella and varicella immunity, syphilis, hepatitis B surface antigen (HBsAg), hepatitis C antibody, opt-out HIV, urine culture for asymptomatic bacteriuria, and chlamydia/gonorrhea screening for women under 25 or at elevated risk.

Last updated: October 2026

Diagnostic Signs of Pregnancy: Classification & Clinical Findings

Establishing the diagnosis of pregnancy relies on clinical history, bimanual physical examination, biochemical laboratory testing, and pelvic ultrasonography. Diagnostic indicators are traditionally divided into three distinct categories based on their diagnostic specificity.

Presumptive Signs (Subjective Symptoms)

Presumptive signs are subjective sensations reported directly by the patient. While suggestive of pregnancy, they lack diagnostic specificity and may be produced by endocrine imbalances, systemic illness, or emotional stress.

Amenorrhea: The cessation of regular menses is usually the earliest sign prompting a patient to seek care. However, it can be caused by functional hypothalamic amenorrhea, polycystic ovary syndrome, thyroid dysfunction, or hyperprolactinemia.

Nausea and Vomiting ("Morning Sickness"): Typically begins between 4 and 6 weeks of gestation, mediated by human chorionic gonadotropin (hCG) and estrogen.

Breast Changes: Tenderness, paresthesias, engorgement, darkening of the areolae, and prominence of Montgomery tubercles.

Fatigue & Somnolence: Profound lethargy induced by the soporific and central nervous system effects of progesterone.

Urinary Frequency: Caused by expanding uterine compression of the bladder within the true pelvis during the first trimester.

Quickening: The maternal perception of fetal movement, typically perceived between 18 and 20 weeks in nulligravidas and as early as 15 to 17 weeks in multigravidas.

Probable Signs (Objective Physical & Laboratory Findings)

Probable signs are objective physical alterations identified by the clinician upon physical examination or laboratory testing. They strongly indicate pregnancy but can occasionally arise from other gynecologic conditions (e.g., pelvic tumors, trophoblastic disease).

Goodell Sign: Marked softening of the vaginal portion of the cervix occurring around 4 to 6 weeks of gestation, caused by increased pelvic vascularity and edema.

Chadwick Sign: Deep bluish-purplish discoloration of the cervix, vagina, and labia minora visible by 6 to 8 weeks, secondary to marked venous engorgement.

Hegar Sign: Softening and extreme compressibility of the lower uterine segment (the uterine isthmus) elicited on bimanual pelvic examination between 6 and 8 weeks.

Uterine Enlargement & Asymmetry (Piskacek Sign): Palpable enlargement of the uterus, often asymmetric early on at the site of blastocyst implantation.

Abdominal Enlargement: Progressive uterine fundal rise palpable above the pubic symphysis by 12 weeks of gestation.

Braxton Hicks Contractions: Painless, irregular, non-rhythmic uterine contractions palpable from the second trimester onward.

Ballottement: Rebound sensation felt by the examiner's fingers against the cervix when tapping the floating fetus in amniotic fluid (at 16–28 weeks).

Positive Pregnancy Test: Biochemical detection of hCG in maternal urine or serum.

Positive Signs (Definitive Objective Proof)

Positive signs are definitive diagnostic evidence attributed exclusively to the presence of a developing fetus. They unequivocally confirm pregnancy.

Auscultation of Fetal Heart Tones: Detection of fetal cardiac activity distinct from the maternal heart rate. Fetal heart rate ranges between 110 and 160 beats per minute, detectable via handheld Doppler by 10 to 12 weeks of gestation (or via DeLee fetoscope / acoustic stethoscope by 18 to 20 weeks).

Palpation of Fetal Movement by the Clinician: Active fetal movements felt through the maternal abdominal wall by an experienced examiner (typically after 20 weeks).

Direct Sonographic Visualization of the Fetus: Transvaginal or transabdominal ultrasonographic visualization of the gestational sac, yolk sac, fetal pole, and embryonic cardiac motion.

Serum & Urine hCG Kinetics & The Discriminatory Zone

Human chorionic gonadotropin (hCG) is a glycoprotein heterodimer synthesized by placental syncytiotrophoblasts following blastocyst implantation. It shares an identical alpha subunit with LH, FSH, and TSH, while its distinct beta subunit confers unique biological and immunological specificity.

Biochemical Kinetics

Detection Window: Beta-hCG enters the maternal circulation immediately upon blastocyst implantation (day 6 to 8 post-conception). It is detectable in maternal serum as early as 8 to 11 days after fertilization .

Home Urine Pregnancy Tests: Immunoassays detect urine beta-hCG at concentrations of 20 to 50 mIU/mL , typically becoming positive on or before the first day of the missed menstrual period.

Doubling Time: In a viable early intrauterine pregnancy, maternal serum beta-hCG concentrations rise exponentially, doubling roughly every 48 hours (a minimum rise of 35% to 53% over 48 hours is expected in viable gestations with baseline hCG <1,500 mIU/mL).

Peak Concentrations: Serum hCG peaks between 8 and 10 weeks of gestation at roughly 100,000 mIU/mL, then declines to a plateau of approximately 20,000 mIU/mL through delivery.

The Ultrasound Discriminatory Zone

The discriminatory zone is the maternal serum beta-hCG concentration above which a normal intrauterine gestational sac must reliably be visualized by transvaginal ultrasonography (TVUS).

Diagnostic Threshold: In high-resolution clinical ultrasound, the discriminatory zone is typically 1,500 to 2,000 mIU/mL ACOG Practice Bulletin 193 cautions that the level may be as high as 3,500 mIU/mL , so a single value should never trigger treatment that could end a viable pregnancy.

Clinical Application: If a patient's serum quantitative beta-hCG is above the discriminatory level and a TVUS demonstrates an empty uterine cavity , an abnormal gestation (such as an ectopic pregnancy, early pregnancy loss, or complete abortion) is suspected until proven otherwise, warranting urgent serial surveillance or laparoscopy.

Early Sonographic Milestones (Transvaginal Ultrasound)

Gestational Sac (4.5 to 5.0 Weeks): First sonographic evidence of pregnancy. Appears as a small, round, hypoechoic fluid collection with an echogenic rim, eccentric to the endometrial stripe (double decidual sac sign), measuring ~2 to 5 mm.

Yolk Sac (5.5 Weeks): Appears as a bright, circular echogenic ring with an anechoic center inside the gestational sac. Confirms an intrauterine pregnancy (distinguishing it from a pseudogestational sac of ectopic pregnancy).

Embryonic Pole with Cardiac Activity (6.0 to 6.5 Weeks): The embryonic pole appears adjacent to the yolk sac. Rhythmic embryonic cardiac activity (fluttering motion) must be present when the crown-rump length (CRL) is ≥7 mm . The absence of cardiac motion with a CRL ≥7 mm confirms early pregnancy loss (embryonic demise) .

Gestational Dating & ACOG/SMFM Redating Criteria

Accurate gestational dating is the cornerstone of obstetric care. It determines the timing of antenatal screening tests, guides decisions regarding preterm labor interventions, and dictates post-term delivery timing.

Naegele's Rule for Estimated Date of Delivery (EDD)

Naegele's rule calculates the EDD based on the first day of the last normal menstrual period (LMP):

Naegele's Rule Formula: EDD = LMP + 7 days − 3 months + 1 year

Clinical Caveat: Naegele's rule assumes a strictly regular 28-day menstrual cycle with ovulation occurring on day 14. In patients with irregular or prolonged cycles, ovulation timing varies, necessitating reliance on first-trimester ultrasound.

Ultrasound Dating Precision & Hierarchy

First-trimester ultrasound measurement of the Crown-Rump Length (CRL) is the single most accurate biometric parameter for dating pregnancy, carrying an error margin of ±5 to 7 days .

  • Gestational Age Range Biometric Dating Parameter Discrepancy Threshold Indicating Redating by Ultrasound
  • ≤8 6/7 weeks Crown-Rump Length (CRL) Discrepancy >5 days between LMP-derived EDD and ultrasound CRL
  • 9 0/7 to 13 6/7 weeks Crown-Rump Length (CRL) Discrepancy >7 days between LMP-derived EDD and ultrasound CRL

14 0/7 to 15 6/7 weeks Composite Biometry (BPD, HC, AC, FL) Discrepancy >7 days between LMP-derived EDD and ultrasound biometry

16 0/7 to 21 6/7 weeks Composite Biometry (BPD, HC, AC, FL) Discrepancy >10 days between LMP-derived EDD and ultrasound biometry

22 0/7 to 27 6/7 weeks Composite Biometry (BPD, HC, AC, FL) Discrepancy >14 days between LMP-derived EDD and ultrasound biometry

≥28 0/7 weeks Composite Biometry (BPD, HC, AC, FL) Discrepancy >21 days between LMP-derived EDD and ultrasound biometry

Important

Rule of Clinical Stability: Once an EDD is established and confirmed by an accurate early first-trimester ultrasound, it is NEVER changed based on subsequent ultrasound examinations later in pregnancy. Later scans reflect biological variation in fetal growth (such as fetal growth restriction or macrosomia) rather than errors in gestational age.

The Comprehensive Initial Prenatal Laboratory Evaluation

The initial prenatal visit establishes a comprehensive baseline of maternal health and screens for asymptomatic conditions that threaten maternal-fetal well-being.

Laboratory Evaluation Clinical Rationale & Diagnostic Target Evidence-Based Clinical Management

Blood Type & Rh(D) Status Identifies Rh(D)-negative gravidas at risk for alloimmunization (isoimmunization) and hemolytic disease of the fetus and newborn (HDFN). If Rh-negative and unsensitized (antibody negative), administer 300 mcg anti-D immune globulin (RhoGAM) at 28 weeks and within 72 hours of delivery of an Rh-positive newborn, or after bleeding, trauma, or an invasive procedure at 12 weeks or later (ACOG 2024 suggests forgoing routine RhIG for loss or abortion before 12 weeks).

Indirect Coombs (Antibody Screen) Detects maternal atypical red cell antibodies (anti-D, Kell, Duffy, Kidd). If positive, quantify maternal antibody titer; titers ≥1:8 to 1:32 warrant paternal antigen testing and middle cerebral artery (MCA) Doppler peak systolic velocity surveillance for fetal anemia.

Complete Blood Count (CBC) Assesses baseline hemoglobin, hematocrit, and platelet count. Anemia in pregnancy is defined as Hb <11.0 g/dL in the 1st/3rd trimesters, or <10.5 g/dL in the 2nd trimester. Thrombocytopenia (<100,000/mcL) warrants evaluation for gestational thrombocytopenia vs. ITP.

Rubella Immunity (IgG Titer) Evaluates susceptibility to Congenital Rubella Syndrome (cataracts, deafness, cardiac defects). If non-immune (equivocal or negative IgG), counsel patient to avoid exposures; administer MMR vaccine immediately postpartum . MMR is live attenuated and strictly contraindicated in pregnancy.

Varicella Immunity (IgG Titer) Evaluates susceptibility to varicella zoster virus. If non-immune, administer Varivax postpartum. If an unimmunized, non-immune gravida is exposed to chickenpox during pregnancy, administer Varicella-Zoster Immune Globulin (VariZIG) within 10 days of exposure.

Syphilis Serology (RPR/VDRL or Treponemal EIA) Screens for Treponema pallidum to prevent congenital syphilis (stillbirth, hydrops, bone deformities, snuffles). ACOG (2024) adds universal rescreening in the third trimester and at delivery. Treat with Benzathine Penicillin G according to stage. Penicillin is the ONLY proven curative agent in pregnancy; patients with a verified penicillin allergy MUST undergo desensitization and treatment with penicillin .

Hepatitis B Surface Antigen (HBsAg) Detects chronic maternal HBV infection to prevent mother-to-child vertical transmission. If maternal HBsAg is positive, neonate must receive Hepatitis B Immune Globulin (HBIG) AND the first dose of Hepatitis B vaccine within 12 hours of birth , reducing vertical transmission by >90%. Maternal viral load >200,000 IU/mL warrants tenofovir in the third trimester.

HIV Screening (Opt-Out) Universal opt-out 4th-generation antigen/antibody screening. Antiretroviral therapy (ART) throughout pregnancy, scheduled cesarean at 38 weeks if viral load is >1,000 copies/mL near delivery, and infant prophylaxis lower transmission from ~25% to <1%. Since 2023, federal perinatal guidelines support shared decision-making about breastfeeding for people with sustained viral suppression.

Hepatitis C Antibody CDC (2020) recommends HCV screening during every pregnancy. Reactive antibody → HCV RNA; arrange postpartum treatment (direct-acting antivirals are not yet routine in pregnancy); breastfeeding is allowed unless nipples are cracked and bleeding.

Urine Culture (Clean Catch Midstream) Screens universally for asymptomatic bacteriuria (defined as ≥100,000 CFU/mL [10⁵ CFU/mL] of a single uropathogen). Progesterone-mediated ureteral dilation and vesicoureteral reflux cause 20% to 30% of untreated asymptomatic bacteriuria to progress to acute pyelonephritis , preterm labor, and sepsis. Treat with a 5- to 7-day course of safe antibiotics (nitrofurantoin, cephalexin, amoxicillin-clavulanate) and obtain a test-of-cure culture 1 to 2 weeks post-treatment .

Chlamydia & Gonorrhea NAAT Universally screened in all pregnant women <25 years of age and older women with new/multiple partners. Untreated infection causes neonatal chlamydial pneumonia, ophthalmia neonatorum, chorioamnionitis, and preterm birth. First-line chlamydia: oral azithromycin 1 g single dose; gonorrhea: intramuscular ceftriaxone 500 mg single dose. Chlamydia needs a test of cure about 4 weeks after treatment in pregnancy, and both infections need retesting at 3 months.

Universal Carrier Screening Cystic fibrosis (CF) and spinal muscular atrophy (SMA) carrier screening offered. Offer to all patients regardless of ancestry; assess partner if patient is a carrier.